SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study
| Autor: | Anna Garmpi, Paraskevi Farmaki, Vasileios Antoniou, Lourdes Victoria Quiles-Sánchez, Eleni Memi, Konstantina Kyre, Georgios Kyriakos, Spyridon Savvanis |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty diabetes type 2 mellitus CVD-REAL study T2DM Class effect Outcome (game theory) Article cardiovascular events 03 medical and health sciences 0302 clinical medicine Internal medicine Diabetes mellitus medicine Humans Hypoglycemic Agents In patient Hypoglycemic drugs Sodium-Glucose Transporter 2 Inhibitors EMPA-REG OUTCOME trial business.industry class effect General Medicine medicine.disease 030104 developmental biology Drug class Diabetes Mellitus Type 2 Cardiovascular Diseases 030220 oncology & carcinogenesis Cardiology and Cardiovascular Medicine business Cardiovascular outcomes SGLT2 inhibitors |
| Zdroj: | Current Cardiology Reviews |
| ISSN: | 1573-403X |
| Popis: | A new group of hypoglycemic drugs has been used to treat diabetes type 2. This group is active sodium glucose co-transporter (SGLT2) or SGLT2 inhibitors. It has been shown that besides the treatment of diabetes, this drug class is responsible for the mildness of the cardiovascular events shown in patients with diabetes type 2. However, there is an intriguing question regarding the range of SGLT2 inhibitors and if there is a difference between them or if there is a class effect among their results. EMPA-REG OUTCOME trial and the CVD-study are used to answer this question. Additional information from the DECLARE-TIMI 58 and Dapa-HF trials is studied. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|